Post Profile

Roche shares hit by trial flops, fears over biosimilar defense

ZURICH (Reuters) - Roche shares fell in early trading on Monday after trial failures added to the Swiss drugmaker's challenge of replacing patent-expired medicines with lucrative new drugs.
read more


Related Posts

Roche cancer drug taking bite out of Bristol's Opdivo

Health : Reuters: Health

ZURICH (Reuters) - Roche's cancer drug Tecentriq hit the market months behind immuno-oncology (I/O) medicines from Merck and Bristol-Myers Squibb Co but the Swiss drugmaker's treatment is making up lost ground.

Mylan deal clears path for biosimilar copy of Roche's Herceptin

Health : Reuters: Health

LONDON (Reuters) - Generic drugmaker Mylan said on Monday it had reached a settlement with Roche providing "a clear pathway" for the launch of its biosimilar version of the Swiss company's top-selling breast cancer drug Herceptin in...

Swiss drugmaker Roche confident sales growth will overcome generic threat

Health : Reuters: Health

ZURICH (Reuters) - Swiss drugmaker Roche, encouraged by better than expected first-quarter sales, said it was confident new drugs will help to deliver revenue and profit growth even as its older medicines take a hit from cheaper cop...

Roche bid for Avastin follow-on suffers blow with trial failure

Health : Reuters: Health

ZURICH (Reuters) - Swiss drugmaker Roche's bid to follow its blockbuster cancer drug Avastin with a newer, better drug took a hit when it announced on Thursday that an investigational therapy had failed in a study against metastatic...

Novartis posts a win, Roche a flop in skin cancer trials

Health : Reuters: Health

ZURICH/MADRID (Reuters) - Swiss drugmaker Novartis notched a trial win for its drug cocktail against skin cancer on Monday, while a rival treatment from Roche with slipping sales failed in a separate study with a similar patient gro...


Copyright © 2016 Regator, LLC